This German Biotech's Novel Approach Just Landed Major Seed Funding

Jan de Vries · 2026-08-28

A new player has entered the European biotech arena with a fresh take on tackling some of the world's most common and challenging diseases. Revier Therapeutics, based in Heidelberg, Germany, has officially launched and closed a significant $6.5 million Seed financing round. The company is laser-focused on developing disease-modifying therapies for cardiometabolic conditions, a massive area of unmet medical need. This isn't just another startup story. It's a glimpse into where cutting-edge European science and smart capital are converging. The funding round was spearheaded by the KHAN Technology Transfer Fund II, with notable participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors via Revier Invest Heidelberg. That's a strong vote of confidence right out of the gate. ### The Core Mission: Beyond Symptom Management What sets Revier apart? Their mission is to move beyond simply managing symptoms. They're targeting the underlying biology that drives diseases like heart failure and atherosclerosis. Prof. Eva van Rooij, PhD, the company's co-founder and CEO, put it bluntly. Despite real progress, millions of patients still face limited, targeted options. She believes the next wave of medicine has to get to the root cause. Their strategy hinges on translating the complex science of a specific enzyme class into real, tangible therapies that can create long-term value for patients and the entire healthcare system. It's a big ambition, but they've got the scientific backing to make it plausible. ### A First-of-its-Kind Therapeutic Strategy Here’s where it gets scientifically fascinating. Revier is pioneering what it calls the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for cardiometabolic diseases. In simpler terms, HDACs are enzymes that play a key role in many severe diseases. Earlier, broader HDAC inhibitors often came with harsh side effects. Revier’s twist? Their orally available small molecules are designed to be precision tools. They aim to inhibit only the disease-causing activity while leaving healthy biological functions untouched. Prof. Johannes Backs, MD, the scientific founder, explained that this selective targeting is designed for therapeutic effectiveness with a much better safety profile. It's a classic case of working smarter, not just harder. - **Initial Focus:** Their pipeline starts with two major indications: heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). - **The Investor Perspective:** Michael Hamacher, PhD, of KHAN, highlighted the company's potential to "unlock the therapeutic promise of HDAC biology" and reshape patient care with more durable benefits. ### What’s Next for the Startup? So, what does a biotech startup do with $6.5 million? For Revier, it's all about fueling their preclinical pipeline. The capital will directly support advancing their lead program in HFpEF and their second program in ASCVD. Just as importantly, it will fund the critical build-out of their operational, scientific, and clinical teams. They're laying the groundwork to move from promising science to clinical reality. The launch of Revier Therapeutics is a solid example of the deep, research-driven innovation happening within the European startup ecosystem. It's a story about specialized science attracting specialized investment, all aimed at solving problems that affect millions globally. For professionals watching the EU biotech and startup incorporation space, it's a company worth keeping on your radar as it progresses from the lab toward the clinic.